Journal of Antimicrobial Chemotherapy · 2006 · 183 citations · 8 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAnaerobic BacteriologyAntibiotic ResistanceAntimicrobial Susceptibility TestingDiagnostic BacteriologyResistance In Gram-positive BacteriaResistance SurveillanceAntibacterial Susceptibility TestingAntibiotic Susceptibility TestingAntimicrobial Resistance MonitoringAntimicrobial Resistance PatternsEscherichia ColiExtended-spectrum Beta-lactamasesMicrobial Susceptibility TestingPhenotypic Characterization Of Isolates
OBJECTIVES: SMART (Study for Monitoring Antimicrobial Resistance Trends) is an ongoing study to monitor worldwide antimicrobial resistance trends among aerobic and facultatively anaerobic Gram-negative bacilli (GNB) isolated from intra-abdominal infections. This 2004 report summarizes the most recently completed annual data from SMART. METHODS: During 2004, 81 medical centres from 28 countries in five global regions collected intra-abdominal GNB for antimicrobial susceptibility testing using broth microdilution according to the Clinical and Laboratory Standards Institute guidelines. RESULTS: A total of 6156 unique aerobic and facultatively anaerobic GNB were isolated from intra-abdominal infections. Enterobacteriaceae composed 86% of the total isolates. Among the 12 antimicrobial agents tested, the carbapenems and amikacin were the most consistently active against the Enterobacteriaceae. Escherichia coli was the most commonly isolated species (48%), and the susceptibility rate to the quinolones was lowest in Asia/Pacific and Latin America. Extended-spectrum beta-lactamases (ESBLs) were detected phenotypically in 10% of E. coli, 17% of Klebsiella spp. and 22% of Enterobacter spp. worldwide, representing a slight increase over the two previous years. ESBL producers typically had a more antibiotic-resistant profile than non-ESBL producers but were usually susceptible to the carbapenems. CONCLUSIONS: Antimicrobial resistance among GNB isolated from intra-abdominal infections continued to be a problem worldwide in 2004, with the highest rates of resistance overall in the Asia/Pacific region. The carbapenems and amikacin were the most consistently active agents in vitro against Enterobacteriaceae isolated from intra-abdominal infections worldwide.
8
Comparative analysis of two rates
Olli S. Miettinen, Markku Nurminen · Statistics in Medicine · 1985 · 1.1K citations
David L. Paterson, Flávia Rossi, Fernando Baquero et al. · Journal of Antimicrobial Chemotherapy · 2005 · 185 citations
Joshua P. Metlay, Warren B. Bilker, Paul H. Edelstein et al. · Clinical Infectious Diseases · 2005 · 118 citations · Full text
Ebbing Lautenbach, Brian L. Strom, Irving Nachamkin et al. · Clinical Infectious Diseases · 2004 · 103 citations · Full text
Jesús Oteo · Journal of Antimicrobial Chemotherapy · 2002 · 80 citations · Full text